Transcriptional inhibition of the human papilloma virus reactivates tumor suppressor p53 in cervical carcinoma cells

Molecular Biology

Volumn 41, Issue 3, 2007, Pages 459-466

  Kochetkov, D V ^a,b   Ilyinskaya, G V ^a,b,c   Komarov, P G ^d,e   Strom, E ^d,e   Agapova, L S ^b,c   Ivanov, A V ^b   Budanov, A V ^a,b   Frolova, E I ^f   Chumakov, P M ^a,b  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b LERNER RESEARCH INSTITUTE   (United States)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d Quark Biotech Inc   (United States)

^e CLEVELAND BIOLABS INC   (United States)

^f SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

galactosidase; Apoptosis; Cervical carcinoma; Chemical library; HeLa cells; Human papilloma virus; p53; Suppression of cell proliferation; Transcriptional reporter construct

Indexed keywords

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18;

EID: 34547351574     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893307030120     Document Type: Article

References (26)

1. Kopnin B.P. 2000. Targets for oncogenes and tumor suppressors: A key to understanding basic mechanisms of carcinogenesis. Biokhimiya. 65, 5-33.
2. Chumakov P.M. The function of p53 gene: A life-or-death choice. Biokhimiya. 65, 34-47.
3. Baker S.J., Fearon E.R., Nigro J.M., Hamilton S.R., Preisinger A.C., Jessup J.M., vanTuinen P., Ledbetter D.H., Barker D.F., Nakamura Y., White R., Vogelstein B. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 244, 217-221.
4. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., Hainaut P. 1999. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res. 431, 199-209.
5. Levine A.J., Perry M.E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. 1994. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer. 69, 409-416.
6. Mantovani F., Banks L. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 20, 7874-7887.
7. Lane D.P., Lain S. 2002. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8, S38-S42.
8. McCormick F. 2003. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2, S157-S160.
9. Vecil G.G., Lang F.F. 2003. Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. 65, 237-246.
10. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science. 286, 2507-2510.
11. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288.
12. zur Hausen H. 1996. Papillomavirus infections: A major cause of human cancers. Biochim. Biophys. Acta. 1288, F55-F78.
13. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63, 1129-1136.
14. Ashcroft M., Vousden K.H. 1999. Regulation of p53 stability. Oncogene. 18, 7637-7643.
15. Schneider-Gadicke A., Schwarz E. 1986. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 5, 2285-2292.
16. Razorenova O.V., Agapova L.S., Budanov A.V., Ivanov A.V., Strunina S.M., Chumakov P.M. 2005. Retroviral reporter systems for assessing the activity of stress-inducible signal transduction pathways controlled by the p53, HIF-1, and HSF-1 transcription factors. Mol. Biol. 39, 286-293.
17. Strunina S.M., Ivanov A,V., Chumakov P.M. 2003. Construction of a reporter system for fine assessment of the p53 activity in cultured cells, Mol. Biol. 37, 1007-1018.
18. Grignani F., Kinsella T., Mencarelli A., Valtieri M., Riganelli D., Lanfrancone L., Peschle C., Nolan G.P., Pelicci P.G. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 58, 14-19.
19. Pietenpol J.A., Tokino T., Thiagalingam S., el-Deiry W.S., Kinzler K.W., Vogelstein B. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA. 91, 1998-2002.
20. Komarova E.A., Chernov M.V., Franks R., Wang K., Armin G., Zelnick C.R., Chin D.M., Bacus S.S., Stark G.R., Gudkov A.V. 1997. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16, 1391-1400.
21. Hietanen S., Lain S., Krausz E., Blattner C., Lane D.P. 2000. Activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci. USA. 97, 8501-8506.
22. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49.
23. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252, 1708-1711.
24. Funk W.D., Pak D.T., Karas R.H., Wright WE., Shay J.W. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866-2871.
25. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75, 817-825.
26. Razorenova O.V., Ivanov A.V., Budanov A.V., Chumakov P.M. 2005. Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene. 350, 89-98.